News and Trends 14 Dec 2022 The crucial importance of project management for healthcare startups By Clémentine Duflot, consultant at HC NEXT In an effervescent healthcare innovation field, where risk-assessment and time-to-market are key to break through and survive, speeding and derisking drug and medical device developments to ensure each innovation becomes a product to benefit patients is essential. A drug or medical device development project requires a high level […] December 14, 2022 - 3 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Startup Scout 13 Dec 2022 Biomemory is making DNA hard drives cheap and sustainable The world is running out of ways to store the mountains of data we produce. Biomemory is creating DNA-based hard drives that could store this information cheaply, sustainably and for centuries. Society has advanced very far in technologies to store critical data, moving from punched cards and floppy disks in the 20th century to hard […] December 13, 2022 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 13 Dec 2022 Watch: Interview with Medicon Village CEO Petter Hartman Medicon Village, in Lund, southern Sweden, is part of a cluster of life science research and development, together with actors such as the European Spallation Source (ESS), the BioMedical Centre (BMC) at Lund University and the Max IV Laboratory. Medicon Village is divided into two companies – Medicon Village Fastighets AB and Medicon Village Innovation […] December 13, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 13 Dec 2022 Ascletis announces positive COVID-19 trial results Ascletis Pharma Inc. has announced positive topline results from its phase I multiple ascending dose (MAD) study in healthy subjects for oral RNA-dependent RNA polymerase (RdRp) inhibitor ASC10 for COVID-19 treatment. Ascletis’ ASC10 is an innovative orally available double prodrug, which has a new and differentiated chemical structure from the single prodrug molnupiravir. After oral […] December 13, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 13 Dec 2022 Therabest and Glycotope to assess breast cancer combination treatment Therabest USA. Inc, Therabest Korea and Glycotope GmbH have signed an agreement to assess the clinical development of Therabest’s EiNK (enhanced iPSC-derived NK) cell therapy, TB-100, in combination with Glycotope’s immuno-cytokine, GT-00AxIL15 in triple-negative breast cancer (TNBC) patients. NK (natural killer) cell therapies from various cell sources have demonstrated exciting results in early clinical trials […] December 13, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 13 Dec 2022 Blood clotting research holds hope for sepsis Researchers from the University of Birmingham in the U.K., who identified a novel mechanism for platelet activation in pathogenic blood clotting (thrombosis), are now turning their attention to sepsis. Identified by associate professor Julie Rayes and Martina Colicchia from the Birmingham Platelet Group, and described in a recent paper in Blood, this previously unknown axis […] December 13, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 13 Dec 2022 Poolbeg influenza trial successfully completed Poolbeg Pharma has received initial results having completed its lipopolysaccharide (LPS) human challenge clinical trial for POLB 001, a viral strain agnostic, small molecule immunomodulator being developed to address the unmet medical need for severe influenza. The study showed no further clinical activity is required to complete the objectives of the trial, bringing the recruitment […] December 13, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Opinion 12 Dec 2022 Artificial intelligence: a new era in rare genetic disease diagnosis Despite the onset of the genomics era, rare disease diagnosis remains a challenge. Nostos Genomics’ co-founder, Rocío Acuña Hidalgo, and chief operating officer, Ansgar Lange, shed light on how artificial intelligence (AI) could fill in the gaps. It is estimated that 300 million people worldwide are affected by rare diseases and around 80% of these […] December 12, 2022 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 12 Dec 2022 Japanese research offers hope for Fukuyama muscular dystrophy patients Fukuyama congenital muscular dystrophy (FCMD) is the second most common form of childhood muscular dystrophy in Japan. The disease manifests itself in the form of a severe neuromuscular disorder. One form of FCMD is caused by a genetic abnormality in the fukutin (FKTN) gene. The genetic anomaly blocks the chemical glycosylation of a biologically important […] December 12, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Dec 2022 OSE Immunotherapeutics announces latest acute lymphoblastic leukemia data OSE Immunotherapeutics SA has presented the latest preclinical data on the use of its anti-IL-7 receptor (IL-7R) antagonist OSE-127 for the treatment of B- and T-Cell acute lymphoblastic leukemia (B- and T-ALL). The information was provided at the American Society of Hematology (ASH) annual meeting in New Orleans, Louisiana. The preclinical data on OSE-127 presented […] December 12, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Dec 2022 Enterome completes patient enrollment for recurrent glioblastoma study Enterome has completed patient enrollment in its phase 2 clinical trial (ROSALIE) evaluating its lead OncoMimics candidate, EO2401, in combination with an immune checkpoint inhibitor (nivolumab) +/- an anti-VEGF therapy (bevacizumab) in patients with first progression/recurrence of glioblastoma, an aggressive form of brain cancer. Enterome is a French clinical stage company developing first-in-class immunomodulatory drugs […] December 12, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Dec 2022 Studying the global spread of antimicrobial resistance An international research team has provided new information about what drives the global spread of genes responsible for antimicrobial resistance (AMR) in bacteria. The collaborative study, led by researchers at the Quadram Institute and the University of East Anglia in the U.K., brought together experts from France, Canada, Germany and the U.K. and will provide […] December 12, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email